Association of SARS-CoV-2 Vaccination During Pregnancy With Pregnancy Outcomes.

ABSTRACT:

Importance

Data about the safety of vaccines against SARS-CoV-2 during pregnancy are limited.

Objective

To examine the risk of adverse pregnancy outcomes after vaccination against SARS-CoV-2 during pregnancy.

Design, setting, and participants

This registry-based retrospective cohort study included 157 521 singleton pregnancies ending after 22 gestational weeks from January 1, 2021, until January 12, 2022 (Sweden), or January 15, 2022 (Norway). The Pregnancy Register in Sweden and the Medical Birth Registry of Norway were linked to vaccination and other registries for identification of exposure and background characteristics.

Exposures

Data on mRNA vaccines-BNT162b2 (Pfizer-BioNTech) and mRNA-1273 (Moderna)-and 1 viral vector vaccine-AZD1222 (AstraZeneca)-were c

SUBMITTER: Magnus MC 

PROVIDER: S-EPMC8949721 | biostudies-literature | 2022 Apr

REPOSITORIES: biostudies-literature